Skip to content

Biopharmaceutical veterans John W. Davies, Ph.D. and Michael D. Bruce, Ph.D. to join executive team

BEDFORD, Mass.--November 01, 2017--Kaleido Biosciences, a clinical-stage biotechnology company developing novel chemistries to unlock the power of the human microbiome, announced today the appointment of John W. Davies, Ph.D. as chief technology officer and Michael D. Bruce, Ph.D. as senior vice president, project, portfolio and alliance management.

“We are excited to welcome John and Michael to our leadership team,” said Michael Bonney, chief executive officer and chair of Kaleido Biosciences. “We are confident that their proven track records and diverse experiences in the biopharmaceutical industry will help accelerate Kaleido’s innovative clinical development programs.”

John W. Davies, Ph.D. will oversee the research and technology platform for Kaleido. John has more than 25 years of experience creating and leading diverse technology teams. He received his Ph.D. in synthetic organic chemistry from University College London, before embarking on postdoctoral studies in the emerging field of computational modeling at GlaxoSmithKline. In 1992, Dr. Davies joined Sandoz in London to carry out computational research in neuroscience, before moving to the United States where he supported a broad range of therapeutic disease areas. John held increasing responsibility for technology disciplines and, at Novartis, was responsible for early discovery informatics, sample management, robotics and automation. During this time, he spearheaded the installation of the new automation platform for high-throughput screening (HTS) and initiated the development of a new $25 million sample management environment in Cambridge. Computationally, he led an initiative that reshaped the data and computational strategy for the Novartis Institutes for BioMedical Research (NIBR) and developed a number of unique industry-leading computational approaches, which resulted in more than 100 publications across the informatics group.

Michael Bruce brings more than 20 years of pharmaceutical and biotech product development experience to Kaleido. Michael was one of the earliest hires at CRISPR Therapeutics, where he built the project, portfolio and alliance management functions, including the buildup and successful launch of alliances with Vertex and Bayer. Michael also worked on product development at Millennium Pharmaceuticals, and joined Wyeth, where he led oncology drug development projects. He was a contributing leader to the successful development of five globally marketed drug products. Michael also led project and portfolio management functions at Pfizer, ultimately leading the project management group and governance bodies for the Phase 0-2 portfolio. He has a B.A. from Williams College and a Ph.D. from Stanford University.

About Kaleido Biosciences

Kaleido Biosciences is a clinical-stage biotechnology company engaged in the development of novel chemistries that unlock the power of the microbiome to revolutionize health. The Company has built the first R&D engine to systematically create, discover, and develop interventions that activate metabolic processes in the microbiome to treat disease and maintain health. Since its founding in 2015 by Flagship VentureLabs, Kaleido has advanced candidate products into clinical studies across programs in rare genetic diseases, oncology and infectious disease, and has generated more than 3,000 days of human clinical data. The Company is also creating consumer products that optimize the microbiome's natural roles in promoting health.

To learn more about Kaleido, its pipeline and its management team, please visit: